Q2: SCYNEXIS Surpasses Forecasts; Nogin Misses the Mark
- August 14th, 2023
- 310 views
SCYNEXIS, Inc. (Nasdaq: SCYX), a biotechnology company, reported second-quarter 2023 earnings of $2.46 per share, surpassing the consensus estimate of $1.55 per share. The company posted quarterly sales of $131.50 million, exceeding analysts' projected revenue of $95.45 million.
$SCYX was trading at $2.94 in after-hours, up $0.14 (+5.00%).
In contrast, Nogin, Inc. (Nasdaq: NOGN), a company in the financial sector, reported a Q2 2023 loss of $(1.13) per share, missing the consensus estimate loss of $(0.90) per share. Moreover, the company generated quarterly sales of $12.70 million, falling short of analysts' expected revenue of $14.94 million.
For the full year 2023, Nogin anticipates net revenue to range between $50 million and $55 million, attributed to the decision to exit low-margin relationships, in comparison to the consensus estimate of $79.24 million in revenue for the period.
In after-hours, $NOGN was trading at $0.80, down $0.18 (-17.95%).
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login